ProKidney Corp.
PROK · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.07 | -0.12 | 0.27 |
| FCF Yield | -78.31% | -27.19% | -22.96% | -13.06% |
| EV / EBITDA | -2.72 | -4.53 | -8.74 | -10.69 |
| Quality | ||||
| ROIC | -11.82% | -11.21% | -13.15% | -10.26% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 1.61 | 0.85 | 0.78 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 906,030.98% | 807,637.42% | 673,766.41% | 423,482.36% |
| Free Cash Flow Growth | -97.28% | 38.15% | -56.99% | 18.71% |
| Safety | ||||
| Net Debt / EBITDA | 2.35 | 2.64 | 2.12 | 2.43 |
| Interest Coverage | -39,709.00 | 0.00 | -25,785.50 | -24,486.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 722.85 | 685.57 | 2,897.76 | -213.93 |